CA2268546A1 - Composition, for the treatment of asthma, containing loratadine and a decongestant - Google Patents

Composition, for the treatment of asthma, containing loratadine and a decongestant Download PDF

Info

Publication number
CA2268546A1
CA2268546A1 CA002268546A CA2268546A CA2268546A1 CA 2268546 A1 CA2268546 A1 CA 2268546A1 CA 002268546 A CA002268546 A CA 002268546A CA 2268546 A CA2268546 A CA 2268546A CA 2268546 A1 CA2268546 A1 CA 2268546A1
Authority
CA
Canada
Prior art keywords
decongestant
loratadine
asthma
pseudoephedrine
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002268546A
Other languages
English (en)
French (fr)
Inventor
Alan G. Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2268546A1 publication Critical patent/CA2268546A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002268546A 1996-10-31 1997-10-29 Composition, for the treatment of asthma, containing loratadine and a decongestant Abandoned CA2268546A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73966996A 1996-10-31 1996-10-31
US08/739,669 1996-10-31
PCT/US1997/019158 WO1998018470A1 (en) 1996-10-31 1997-10-29 Composition, for the treatment of asthma, containing loratadine and a decongestant

Publications (1)

Publication Number Publication Date
CA2268546A1 true CA2268546A1 (en) 1998-05-07

Family

ID=24973307

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002268546A Abandoned CA2268546A1 (en) 1996-10-31 1997-10-29 Composition, for the treatment of asthma, containing loratadine and a decongestant

Country Status (21)

Country Link
EP (1) EP0941091A1 (pt)
JP (1) JP2000505104A (pt)
KR (1) KR20000052922A (pt)
CN (1) CN1235545A (pt)
AR (1) AR008908A1 (pt)
AU (1) AU731756B2 (pt)
BR (1) BR9712705A (pt)
CA (1) CA2268546A1 (pt)
CO (1) CO4910128A1 (pt)
CZ (1) CZ150999A3 (pt)
HU (1) HUP9904075A3 (pt)
ID (1) ID23431A (pt)
IL (1) IL129662A0 (pt)
NO (1) NO992062L (pt)
NZ (1) NZ335078A (pt)
PE (1) PE11399A1 (pt)
PL (1) PL333056A1 (pt)
SK (1) SK54599A3 (pt)
TR (1) TR199901003T2 (pt)
WO (1) WO1998018470A1 (pt)
ZA (1) ZA979731B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270796B1 (en) * 1997-10-29 2001-08-07 Robert E. Weinstein Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
PA8481801A1 (es) * 1998-09-10 2000-09-29 Schering Corp Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
ATE253354T1 (de) * 1999-02-23 2003-11-15 Yuhan Corp Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
KR100505899B1 (ko) * 1999-02-23 2005-08-01 주식회사유한양행 로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
WO2000057880A1 (en) * 1999-03-29 2000-10-05 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
SK287105B6 (sk) * 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
JP5592042B2 (ja) * 2000-04-14 2014-09-17 ジェイ−メド ファーマシューティカルズ，インコーポレーティッド 鼻炎治療のための単一投与抗ヒスタミン薬／鬱血除去薬製剤
PA8517201A1 (es) * 2000-05-25 2002-08-26 Schering Corp Composiciones farmaceuticas antihistaminicas anticongestivas liquidas estables
CA2450583A1 (en) * 2001-06-20 2003-01-03 Schering Corporation Antihistamines for the treatment of nasal congestion and nasal obstruction
NZ588134A (en) 2005-06-17 2010-11-26 Aft Pharmaceuticals Ltd Novel pharmaceutical for use in a method for treatment of upper respiratory mucosal congestion
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
JP5175278B2 (ja) * 2006-06-01 2013-04-03 エムエスディー コンシューマー ケア， インコーポレイテッド 結腸吸収のためのフェニレフリン薬学的製剤および組成物
KR101540191B1 (ko) * 2014-02-24 2015-07-28 성균관대학교산학협력단 로라타딘을 포함하는 항염증용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1110397A (en) * 1964-10-02 1968-04-18 Mead Johnson & Co Ephedrine composition
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Also Published As

Publication number Publication date
BR9712705A (pt) 1999-10-26
NO992062D0 (no) 1999-04-29
PL333056A1 (en) 1999-11-08
CN1235545A (zh) 1999-11-17
IL129662A0 (en) 2000-02-29
WO1998018470A1 (en) 1998-05-07
CZ150999A3 (cs) 1999-10-13
AU731756B2 (en) 2001-04-05
ZA979731B (en) 1998-04-29
AU4995397A (en) 1998-05-22
HUP9904075A2 (hu) 2000-05-28
SK54599A3 (en) 2000-08-14
EP0941091A1 (en) 1999-09-15
HUP9904075A3 (en) 2002-02-28
JP2000505104A (ja) 2000-04-25
TR199901003T2 (xx) 1999-07-21
PE11399A1 (es) 1999-02-09
AR008908A1 (es) 2000-02-23
ID23431A (id) 2000-04-20
CO4910128A1 (es) 2000-04-24
NO992062L (no) 1999-04-29
KR20000052922A (ko) 2000-08-25
NZ335078A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
AU731756B2 (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
EP1446119B1 (en) Compositions comprising ipatropium and xylometazoline for treatment of the common cold
Aaronson Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma
KR101841442B1 (ko) 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
US20060276495A1 (en) Treatment methods of nasal congestion and nasal obstruction
Bousquet et al. A 12‐week, placebo‐controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis
Corren et al. Comparison of once‐daily mometasone furoate versus once‐daily budesonide in patients with moderate persistent asthma
Nightingale et al. Comparison of the effects of salmeterol and formoterol in patients with severe asthma
Georgitis et al. Ipratropium bromide nasal spray in non‐allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life
Kilfeather et al. Improved delivery of ipratropium bromide/fenoterol from Respimat® Soft MistTM Inhaler in patients with COPD
US20040092519A1 (en) New treatment for hot flashes
von Berg et al. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma
Von Berg et al. Efficacy and tolerability of formoterol Turbuhaler® in children
Mattson et al. Preventive effect of ketotifen, a new antiallergic agent, on histamine‐induced bronchoconstriction in asthmatics
Kaiser et al. Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis
Ishizuka et al. Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma.
Corren et al. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions
MXPA99003936A (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
WO2008079256A2 (en) Methods for treating nasal congestion in hypertensive or diabetic patients
EP1569650B1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
Frew et al. Effects of 4-week treatment with low-dose budesonide (100 μg BID) from a novel inhaler AirmaxTM and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma
WO2008085392A1 (en) Methods for treating nasal congestion in hepatically impaired patients
McDonald et al. Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction
White et al. Comparative effects of fexofenadine and montelukast on allergen-induced wheal and flare
Chuchalin et al. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler™) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer®) in children with persistent asthma

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued